Evaluating the impact of prior assumptions in Bayesian biostatistics

Statistics in Biosciences

Volumn 2, Issue 1, 2010, Pages 1-17

  Morita, Satoshi ^a   Thall, Peter F ^b   Müller, Peter ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bayesian analysis; Bayesian biostatistics; Bayesian clinical trial design; Effective sample size; Parametric prior distribution

Indexed keywords

ARTICLE; BAYES THEOREM; BIOMEDICINE; BIOSTATISTICS; CALIBRATION; CLINICAL STUDY; DATA ANALYSIS; DIAGNOSTIC TEST; DOSE CALCULATION; DRUG EFFICACY; METHODOLOGY; OUTCOMES RESEARCH; PARAMETRIC TEST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SAMPLE SIZE; SENSITIVITY ANALYSIS; VARIANCE;

EID: 77949559356     PISSN: 18671764     EISSN: 18671772     Source Type: Journal    
DOI: 10.1007/s12561-010-9018-x     Document Type: Article

References (11)

1. Carlin JB (2002) Assessing the homogeneity of three odds ratios: A case study in small- sample inference. In: Gatsonis C, Robert EK, Carlin B, Carriquiry A, Gelman A, Verdinelli I, West M (eds) Case studies in Bayesian statistics, vol V. Springer, New York, pp 279-290.
2. Cheung YK, Chappell R (2000) Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56: 1177-1182.
3. Choi YK, Johnson WO, Collins MT, Gardner IA (2006) Bayesian inferences for receiver operating characteristic curves in the absence of a gold standard. J Agric Biol Environ Stat 11: 210-229.
4. Congdon P (2003) Applied Bayesian modelling. Wiley, Chichester.
5. Elkind MS, Sacco RL, MacArthur RB, Fink DJ, Peerschke E, Andrews H, Neils G, Stillman J, Corporan T, Leifer D, Cheung K (2008) The neuroprotection with statin therapy for acute recovery trial (NeuSTART): An adaptive design phase i dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke 3: 210-218.
6. Gelman A, Carlin JB, Stern HS, Rubin DB (2004) Bayesian data analysis, 2nd edn. Chapman and Hall/CRC, New York.
7. Morita S, Thall PF, Müller P (2008) Determining the effective sample size of a parametric prior. Biometrics 64: 595-602.
8. Morita S, Thall PF, Müller P (2009) Prior effective sample size in conditionally independent hierarchical models. Technical Report, Yokohama City University.
9. O'Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46: 33-48.
10. Thall PF, Cook JD (2004) Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60: 684-693.
11. Thall PF, Wooten LH, Tannir NM (2005) Monitoring event times in early phase clinical trials: Some practical issues. Clin Trials 2: 467-478.